Recombinant Human IL-28B/IFN-lambda 3 Protein


There are currently no images for IL-28B/IFN-lambda 3 (5259-IL).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human IL-28B/IFN-lambda 3 Protein Summary

Details of Functionality
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 1-5 ng/mL.
Chinese Hamster Ovary cell line, CHO-derived human IL-28B/IFN-lambda 3 protein
Arg30-Val200, with the variant of Lys74Arg and a C-terminal 6-His tag
Accession #
N-terminal Sequence
Protein/Peptide Type
Recombinant Proteins
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


Theoretical MW
20.1 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
22 kDa, reducing conditions
Read Publications using
5259-IL in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS, NaCl and EDTA with BSA as a carrier protein.
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-28B/IFN-lambda 3 Protein

  • interleukin-28B
  • IFN-lambda 3
  • IL28B
  • IL-28B
  • IL28C
  • interferon, lambda 3


IL-28B (also named interferon-lambda 3, IFN-lambda 3), IL-28A (IFN-lambda 2) and IL-29 (IFN-lambda 1) are type III interferons that are class II cytokine receptor ligands (1-4). They are distantly related to members of the IL-10 family and type I IFN family (1- 4). Human IL-28B cDNA encodes a 200 amino acid (aa) protein with a 25 aa signal peptide and a 175 aa mature protein that lacks N-glycosylation sites. Mature human IL-28B shares 64% and 75% aa sequence identity with mouse and canine IL-28B, respectively, and is active across species (5). Human IL-28B shares 94% and 69% aa identity with human IL-28A and IL‑29, respectively (4). Type III interferons are widely expressed, but are mainly produced by antigen presenting cells in response to viruses and double-stranded RNA that interact with Toll-like receptors or RIG-1 family helicases (2-6). They signal through a widely expressed receptor that is a heterodimer of the IL-10 receptor beta (IL-10 R beta ) and IL-28 receptor alpha (IL-28 R alpha ; also called IFN-lambda R1) (2, 3, 7, 9). Interaction of either type I or type III IFNs with their receptors activates similar pathways, including JAK tyrosine kinase activation, STAT phosphorylation and formation of the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex (1-3). Both type I and III IFNs induce anti‑viral activity and up‑regulate MHC class I antigen expression (2-6). Cell lines responsive to type III IFNs are also responsive to type I IFNs, but in general, higher concentrations of type III IFNs are needed for similar in vitro responses (8). In vivo, however, type III IFNs enhance levels of IFN-gamma in serum, suggesting that the robust anti-viral activity of type III IFNs may stem in part from activation of the immune system (5, 7). Anti-proliferative and antitumor activity in vivo has also been shown for type III IFNs (9-11).

  1. Chen, Q. et al. (2006) Vitam. Horm. 74:207.
  2. Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
  3. Kotenko, S.V. et al. (2003) Nat. Immunol. 4:69.
  4. Bartlett, N.W. et al. (2005) J. Gen. Virol. 86:1589.
  5. Ank, N. et al. (2006) J. Virol. 80:4501.
  6. Onoguchi, K. et al. (2007) J. Biol. Chem. 282:7576.
  7. Siebler, J. et al. (2007) Gastroenterology 132:358.
  8. Meager, A. et al. (2005) Cytokine 31:109.
  9. Lasfar, A. et al. (2006) Cancer Res. 66:4468.
  10. Sato, A. et al. (2006) J. Immunol. 176:7686.
  11. Zitzmann, K. et al. (2006) Biochem. Biophys. Res. Commun. 344:1334.

Customers Who Viewed This Item Also Viewed...

Species: Hu, Mu, Rt
Applications: WB, Flow, IHC, IHC-P
Species: Hu, Mu, Rt, Bv, Ha, Pm
Applications: WB, Flow, ICC/IF, IHC, IHC-P, IM, IP
Species: Hu, Mu, Rt
Applications: WB, Flow, ICC/IF, IHC, IHC-P
Species: Hu
Applications: WB, ICC/IF, IHC, IHC-P
Species: Hu
Applications: WB, ELISA, ICC/IF
Species: Hu
Applications: WB, Flow, CyTOF-ready, Neut
Species: Hu
Applications: WB, IHC, CyTOF-ready, ICFlow
Species: Hu
Applications: WB
Species: Hu
Species: Hu, Mu, Rt
Applications: WB, ICC/IF, IHC, IHC-P
Species: Hu, Pm
Applications: WB, Flow, IHC, IHC-Fr, CyTOF-ready
Species: Hu, Mu, Rt, Ca, Rb
Applications: WB, Simple Western, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu
Applications: Bioactivity

Publications for IL-28B/IFN-lambda 3 (5259-IL)(10)

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Bioassay.

Filter By Application
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 10.
Publications using 5259-IL Applications Species
PS Sung, SH Hong, JH Chung, S Kim, SH Park, HM Kim, SK Yoon, EC Shin IFN-?4 potently blocks IFN-? signalling by ISG15 and USP18 in hepatitis C virus infection Sci Rep, 2017;7(1):3821. 2017 [PMID: 28630501] (Bioassay, Human) Bioassay Human
Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling Nat. Med., 2016;0(0):. 2016 [PMID: 27841874] (Bioassay, Human) Bioassay Human
Immune Cell Profiling of IFN-? Response Shows pDCs Express Highest Level of IFN-?R1 and Are Directly Responsive Via the JAK-STAT Pathway J Interferon Cytokine Res, 2016;0(0):. 2016 [PMID: 27617757] (Bioassay, Human) Bioassay Human
Resistin reinforces interferon ?-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms Sci Rep, 2016;6(0):30799. 2016 [PMID: 27477870] (Bioassay, Human) Bioassay Human
Banos-Lara M, Harvey L, Mendoza A, Simms D, Chouljenko V, Wakamatsu N, Kousoulas K, Guerrero-Plata A Impact and regulation of lambda interferon response in human metapneumovirus infection. J Virol, 2015;89(1):730-42. 2015 [PMID: 25355870] (Bioassay, Human) Bioassay Human
Persson B, Jaffe A, Fearns R, Danahay H Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS ONE, 2014;9(7):e102368. 2014 [PMID: 25033192] (Bioassay, Human) Bioassay Human
Ding S, Khoury-Hanold W, Iwasaki A, Robek M Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol, 2014;12(1):e1001758. 2014 [PMID: 24409098] (Bioassay, Human) Bioassay Human
Stone, Amy E L, Giugliano, Silvia, Schnell, Gretja, Cheng, Linling, Leahy, Katelyn, Golden-Mason, Lucy, Gale, Michael, Rosen, Hugo R Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog, 2013;9(4):e1003316. 2013 [PMID: 23637605] (Bioassay, Human) Bioassay Human
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012;487(7408):505-9. 2012 [PMID: 22763448] (Bioassay, Human) Bioassay Human
Liu MQ, Zhou DJ, Wang X, Zhou W, Ye L, Li JL, Wang YZ, Ho WZ IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS ONE, 2012;7(4):e35902. 2012 [PMID: 22558263] (Bioassay, Human) Bioassay Human

Reviews for IL-28B/IFN-lambda 3 (5259-IL) (0)

There are no reviews for IL-28B/IFN-lambda 3 (5259-IL). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
  • 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen

FAQs for IL-28B/IFN-lambda 3 (5259-IL) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional Array Products

Bioinformatics Tool for IL-28B/IFN-lambda 3 (5259-IL)

Discover related pathways, diseases and genes to IL-28B/IFN-lambda 3 (5259-IL). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Blogs on IL-28B/IFN-lambda 3

There are no specific blogs for IL-28B/IFN-lambda 3, but you can read our latest blog posts.

Customers Who Bought This Also Bought

CD4 Antibody

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human IL-28B/IFN-lambda 3 Protein and receive a gift card or discount.


Gene Symbol IFNL3